<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185677</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/07</org_study_id>
    <nct_id>NCT02185677</nct_id>
  </id_info>
  <brief_title>Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy</brief_title>
  <acronym>CogAMS</acronym>
  <official_title>Comparison of Cognitive and Behavioral Dysexecutive Syndrome Between Parkinsonian Form and Cerebellar Form of Multiple System Atrophy and Analysis of Correlates With an Imaging Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to compare the score to the Behavioral Dysexecutive&#xD;
      Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and&#xD;
      cerebellar Multiple System Atrophy (MSA-C) patients matched on disease duration, age (± 7&#xD;
      years) and sex .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by&#xD;
      a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and&#xD;
      additional signs. According to the consensus criteria for the diagnosis of MSA, the presence&#xD;
      of dementia is considered an exclusion criteria. However, several studies have reported&#xD;
      cognitive impairment in patients with MSA, dominated by a dysexecutive syndrome. Some studies&#xD;
      have compared the cognitive profile of MSA-P patients and MSA-C but any have studied the&#xD;
      behavioral dysexecutive syndrome in this population. In 2010, the GREFFEX has established&#xD;
      criteria for dysexecutive syndrome and described two distinct parts: the dysexecutive&#xD;
      syndrome and cognitive behavioral dysexecutive syndrome. Our clinical impression is that&#xD;
      according to the type of MSA, the dysexecutive syndrome seems to be different : the MSA-P&#xD;
      patients seem to have a cognitive dysexecutive syndrome and the MSA-C patients a behavioral&#xD;
      dysexecutive syndrome.&#xD;
&#xD;
      We want to compare the BDSI score between MSA-P patients and MSA-C patients matched on&#xD;
      disease duration, age and sex The specific involvement of the cerebellum in behavioral&#xD;
      disorders could explain the behavioral differences experienced by clinicians caring for these&#xD;
      patients but never demonstrated. The presence of these disorders could have an impact on the&#xD;
      relationship between the patient and the caregiver. In addition, few studies have correlated&#xD;
      with cognitive imagery data. Therefore, the exact areas involved in cognitive and behavioral&#xD;
      MSApatients remain poorly understood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">June 26, 2015</completion_date>
  <primary_completion_date type="Actual">June 25, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral Dysexecutive Syndrome Inventory scores</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the subscores of the BDSI between MSA-P patients and MSA-C patients.</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the cognitive tests exploring the cognitive dysexecutive syndrome between MSA-P patients and MSA-C patients.</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Trail making Test&#xD;
Stroop Test&#xD;
Modfied Card Sorting Test&#xD;
Brixton Test&#xD;
Verbal fluency Test&#xD;
Six Elements Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To research correlations between scores UMSARS and cognitive and behavioral scores for MSA-P patients and MSA-C patients.</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
    <description>Assessment using the Behavioral Dysexecutive Syndrome Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare atrophied brain areas, the anatomic and functional abnormalities of neural networks between MSA-P patients and MSA-C patients.</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To research correlations between imaging abnormalities and cognitive test performance in MSA patients.</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphy</measure>
    <time_frame>During 7 days after inclusion</time_frame>
    <description>Sleep analysis :&#xD;
Sleep / wake cycles and sleep fragmentation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>MSA-P</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MSA-C</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation</intervention_name>
    <arm_group_label>MSA-C</arm_group_label>
    <arm_group_label>MSA-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological battery test</intervention_name>
    <arm_group_label>MSA-C</arm_group_label>
    <arm_group_label>MSA-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>MSA-C</arm_group_label>
    <arm_group_label>MSA-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Actigraphy</intervention_name>
    <description>Actigraphy recording will be performed during 7 days after inclusion.</description>
    <arm_group_label>MSA-C</arm_group_label>
    <arm_group_label>MSA-P</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from MSA-P or MSA-C&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients suffering from &quot;probable&quot; MSA according to clinical consensus criteria&#xD;
             (Gilman et al, 2008),&#xD;
&#xD;
          -  Age &gt;30&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient covered by the national health system&#xD;
&#xD;
          -  The presence of an informant&#xD;
&#xD;
          -  Blood negative dosage of the hormone béta-hCG for the women old enough to procreate&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  UMSARS IV score &gt; 4 points&#xD;
&#xD;
          -  Pregnant woman (blood positive dosage of the hormone béta-hCG) or breast feeding&#xD;
&#xD;
          -  Patient under tutelage&#xD;
&#xD;
          -  Patient unable to give consent&#xD;
&#xD;
          -  Against indication to perform an MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra FOUBERT-SAMIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodolphe THIEBAUT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dysexecutive syndrome</keyword>
  <keyword>multiple system atrophy</keyword>
  <keyword>imaging study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

